Necrostatin-1

For research use only.

Catalog No.S8037

62 publications

Necrostatin-1 Chemical Structure

CAS No. 4311-88-0

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 127 In stock
EUR 95 In stock
EUR 265 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Necrostatin-1 has been cited by 62 publications

Purity & Quality Control

Choose Selective RIP kinase Inhibitors

Biological Activity

Description Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
Features A powerful tool for characterizing the role of necroptosis with characterized primary target.
Targets
RIP1 [1]
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M4XlNGNmdGxiVnnhZoltcXS7IFHzd4F6 Mmr5OVDDqM7:TR?= MUiyOOKhcA>? MmXrbY5pcWKrdIOgUW1UNWmwZIXj[YQh[2WubDDk[YF1cA>? NGX2PFgzPjR5MkeyNy=>
MEFs  NHf2VWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEnaeY4yOOLCid88US=> MUm0PEBp Mn7ESG1UVw>? NFXFXYJqdmirYnn0d{B7XkGGLYDyc41wfGWmIHTlZZRpKG:oIFPOU3Q{NWSncHzleIVlKE2HRoO= Mmj2NlY1Ozd5OEm=
BMDM  NY\kbpU1TnWwY4Tpc44hSXO|YYm= MVixNOKh|ryP MmTiN|DDqG2rbh?= NF32colxem:2ZXP0d{Bk\WyuczDmdo9uKFSDS1mtbY5lfWOnZDDMSGghemWuZXHz[S=> MXmyOlM5OTZyMR?=
NCI-H28 M4DiW2NmdGxiVnnhZoltcXS7IFHzd4F6 MlLENVDDqM7:TR?= MnnBNlTDqGh? M17C[5Bz\X[nboTzJGRCWEVvaX7keYNm\CC{ZXT1Z5Rqd25ib3[gUmNKNUh{ODDj[YxtKH[rYXLpcIl1gcLi NUm0fId3OjZyMESxN|g>
MiaPaCa-2 MmjqSpVv[3Srb36gRZN{[Xl? MkD3NlAh|ryP MkD2NlQhcA>? M4LLXYRm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO= M2fkeFI3ODByNkC3
BxPC-3 NGnCZVhHfW6ldHnvckBCe3OjeR?= M3LyU|IxKM7:TR?= NIC5PIczPCCq MYnk[YNz\WG|ZYOgeIhmKGWjcnz5JI5m[3KxdHnjJINmdGy| M1S3O|I3ODByNkC3
SGC-7901 M4i1VWNmdGxiVnnhZoltcXS7IFHzd4F6 M3PoUVMxyqEQvF2= NV7ZfVhCOcLiaB?= MmPFd5VxeHKnc4Pld{BwgGGuaYDsZZRqdi2vZXTpZZRm\CClZXzsJIRm[XSq MXKyOVc3PzB5Nh?=
KMS-12-PE  MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEjjWIY3OCEQvF2= MVW1JIg> M1PaNolvcGmkaYTzJHNJUy2rbnT1Z4VlKGOnbHyg[IVifGh? NFfGfIYzPTV|MEC5PC=>
L929-A  M2jOfWNmdGxiVnnhZoltcXS7IFHzd4F6 MoDJOVDDqM7:TdMg MUGyOEBp M2TKS4Jtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh? MXGyOVM6QDV2MB?=
L929-N  Mk\5R4VtdCCYaXHibYxqfHliQYPzZZk> MYC1NOKh|ryPwrC= NHjVXVYzPCCq NUnETIhV[myxY3vzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aB?= NIHmRoEzPTN7OEW0NC=>
L929-A  NFKxepZHfW6ldHnvckBCe3OjeR?= NELIdpE2OMLizszNxsA> Mk\iNVIhcA>? MkDuZoxw[2u|IITo[UBkdGWjdnHn[UBw\iCFYYPwZZNmNTNiYX7kJHBCWlB? MnzSNlU{QTh3NEC=
L929-N  Mle5SpVv[3Srb36gRZN{[Xl? NGi1cJI2OMLizszNxsA> NWjkSppkOTJiaB?= NEfBNo1jdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= MXWyOVM6QDV2MB?=
L929 NWPnO3dXTnWwY4Tpc44hSXO|YYm= Mn\LOVDDqM7:TdMg M1TKW|EzKGh? NIDMNItqdmirYnn0d{BVVkcQsT3pcoR2[2WmIFLp[EBkdGWjdnHn[S=> MV[yOVM6QDV2MB?=
L929-A NVr1ZWExTnWwY4Tpc44hSXO|YYm= NV3ObolMPTEEoN88UeKh MVuxNkBp MX7pcohq[mm2czD0bIUhXE6IzsGtbY5lfWOnZDDsc5N{KG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheGW{bXXhZoltcXS7 M1;VRlI2Ozl6NUSw
L929 M13zeWNmdGxiVnnhZoltcXS7IFHzd4F6 M2PJTlMxyqEQvF2= NH\wZ|AyyqCq M{Xs[4lvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> NXvZ[3V2OjVyOUW3OFI>
L929 NVTrNlg2S2WubDDWbYFjcWyrdImgRZN{[Xl? NF3lfG8{OMLizszN NIHRO5MyyqCq M3LNNolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPs[YF3[WenIH;mJHRweG9iSR?= M3Ha[VI2ODl3N{Sy
Huh7 MlixR4VtdCCYaXHibYxqfHliQYPzZZk> MUG1NEDDvU1? MlTRNlQwPDhiaB?= NYLXT|ZETE2VTx?= MX3wdoV3\W62czDj[YxtKGSnYYToJI9nKHKDZFjDWkBkdy2rbn\lZ5Rm\CCKdXi3JINmdGy| NF25eWUzPDl5M{K0NC=>
OHC MVzGeY5kfGmxbjDBd5NigQ>? NF7FOW0{ODEkgJpOwG0> M2DrR2ROW09? MlTBbY5kemWjc3XzJI5wcXOnLXnu[JVk\WRiY3;u[IVve2WmIH71Z4xmcQ>? MW[yOFg4PDd|NB?=
OHC MWfGeY5kfGmxbjDBd5NigQ>? NFHsbVk{ODEkgJpOwG0> NGG2R25FVVOR MoG3[IVkemWjc3XzJI5wcXOnLXnu[JVk\WRic4fvcIxmdiCwdXPs[YnDqA>? MkHxNlQ5PzR5M{S=
OHC NIjmc3RHfW6ldHnvckBCe3OjeR?= MoPKN|Ax6oDLzszN NG\VR|BFVVOR M3LFbJJme3WudIOgbY4h[SC{ZXT1Z5Rqd25ib3[gco9qe2VvaX7keYNm\CCUSWCxJIFv\CCUSWCzJIludXWwb3\seY9z\XOlZX7j[S=> MlrxNlQ5PzR5M{S=
OHC NUPsRmNXTnWwY4Tpc44hSXO|YYm= MnzMN|Ax6oDLzszN MnLVSG1UVw>? MoXK[IlucW6rc3jld{Bvd2m|ZT3pcoR2[2WmIFHNVGsh[WO2aY\heIlwdg>? MlPFNlQ5PzR5M{S=
OHC MULGeY5kfGmxbjDBd5NigQ>? NHnDNIY{ODEkgJpOwG0> M1HDOGROW09? MoDubY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiYYDvdJRwfGmlIF;IR5Mhf2m2aH;1eEBidHSncnnu[{B1cGVibHX2[Yx{KG:oIFPDPEBi\nSncjDuc4l{\SCneIDvd5Vz\Q>? NXjGTXJzOjR6N{S3N|Q>
SK-Hep1 NWXRZXFHTnWwY4Tpc44hSXO|YYm= NWnPcpVEPjEkgJpOwG3DqA>? M3TiXlE56oDLaB?= MUDicI9kc3QEoN8yMYxieGGlaH;u[U1qdmS3Y3XkJI1wenCqb3zv[4lk[WxiY3jhcodmNCClZXzsJIRm[XSqIHHu[EBRUSC3cIThb4U> MoThNlQ5OzJ4MEK=
SK-Hep1 MonSSpVv[3Srb36gRZN{[Xl? MVe2NQKBkc7:TdMg NGrQb3gyQOLCiXi= MoT1bY5pcWKrdIOg{tIuVGGyYXPoc45mNWmwZIXj[YQhdGWja3Hn[UBw\iCKTVfCMVHDqA>? M4LV[|I1QDN{NkCy
SK-Hep1 MUnGeY5kfGmxbjDBd5NigQ>? NYPGW|JUPjEkgJpOwG3DqA>? NUHDXnRPOTkkgJno MX\icI9kc3QEoN8yMYxieGGlaH;u[U1u\WSrYYTl[EBRSVJiYXPjeY12dGG2aX;uJIFv\CCDSV[geJJidnOub3PheIlwdiC2bzD0bIUh[3m2b4PvcOKh M{PTR|I1QDN{NkCy
L-540  MYXGeY5kfGmxbjDBd5NigQ>? MnT0OlDjiIoQvH2= NImzVFgy6oDLaB?= M{S5bZBz\X[nboTzJJRp\SCpZX7ldoF1cW:wIH;mJHJQWw>? NILvcGkzPDV4MUWxPS=>
L-540  NXXTelNuTnWwY4Tpc44hSXO|YYm= NF\DZ4w3OOLCid88cS=> NF25[Igy6oDLaB?= Mn7DdJJmfmWwdIOgeIhmKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? NFPLeWQzPDV4MUWxPS=>
L-540  MoTnR4VtdCCYaXHibYxqfHliQYPzZZk> NGjGd4I3OOLCid88cS=> M{i4e|HjiImq NIHLSpJz\WS3Y3XzJJRp\SCJaY\pco9{fGG2L2PvdoFn\W6rYj3pcoR2[2WmIHPlcIwh\GWjdHi= M1nhOlI1PTZzNUG5
AGS NUmyWZRmS2WubDDWbYFjcWyrdImgRZN{[Xl? NInEU5U3OOLCid88cS=> M2DtO|HjiImq NXfUb494eHKndnXueJMhe2ira3;ubY4ucW6mdXPl[EBk\WyuIHTlZZRp Mlq5NlQ1PjNzOUm=
NRK-52E  Mn\hR4VtdCCYaXHibYxqfHliQYPzZZk> NF7QTJUzOCEQvF2= M3\OfVI1KGh? Ml;KdJJwfGWldIOgZ4VtdHNiZoLvcUBk\WyuIHTlZZRpKGOjdYPl[EBjgSCrc3Po[Y1q[SCrbnr1dpk> NWjyR|JyOjR|NUG4OFU>
NRK-52E  MkLnR4VtdCCYaXHibYxqfHliQYPzZZk> NGX1e2UzOCEQvF2= M2SxWVI1KGh? MnTRbY5kemWjc3XzJINmdGxidnnhZoltcXS7IHHmeIVzKFSQRj5OtUBUfGmvdXzheIlwdiCjbnSgRXRRKESncHzleIlwdg>? Ml;zNlQ{PTF6NEW=
NRK-52E  NXrh[HpuS2WubDDWbYFjcWyrdImgRZN{[Xl? MW[yNEDPxE1? MkjiNlQhcA>? NWjYUW1qcW6qaXLpeJMhcW6lcnXhd4VlKES{cEGgdJJwfGWrbjDlfJBz\XO|aX;uJIFnfGW{IGTOSk3PuSCVdHnteYxifGmxbjDhcoQhSVSSIFTldIxmfGmxbh?= MmHJNlQ{PTF6NEW=
L929 M{X3bGZ2dmO2aX;uJGF{e2G7 Ml;sNk82yqEQvHevcYzDqA>? M4D1OFI1yqCq NFn6UIJz\X[ncoPl[EB1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG5H|rFiYXzvcoUh[XNid3XscEBieyCWTldOteKhM8Liem\BSC=> Mn7xNlM6PDF5Nkm=
L929 NF7SZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH6dHUzNzYEoN88[{9udMLi MX:yOOKhcA>? NESxW2Fz\X[ncoPld{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ> Mm\HNlM6PDF5Nkm=
L929 NEXKO4xHfW6ldHnvckBCe3OjeR?= NVG3PFVbOsLizsznM41tyqB? Ml7LNlTDqGh? MnjudJJwdW:2czDjZZNx[XOnLU[gLJAzOCliYXP0bZZqfHliYX7kJJBzd2Ojc4Dhd4UuPiClbHXheoFo\Q>? MlXKNlM6PDF5Nkm=
L929 NUj5XmFRTnWwY4Tpc44hSXO|YYm= M4\xclXDqM7:Zz;tcC=> NI\6VWszPMLiaB?= NViwZYd[[myxY3vzJJpXSURiaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 M17OOlI{QTRzN{[5
C6 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{m3e|EhdW2xbD;M M3T2ZlMhcA>? NEjvPGxifHSnboXheIV{KFOqaXvvcolvKGmwZIXj[YQh\2yrb33hJINmdGxiZHXheIg> NYTnOIpYOjN6NEC0OFE>
U87 NGW1PYxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnTNNUBudW:uL1y= M175WFMhcA>? MV7heJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi= MXuyN|g1ODR2MR?=
C6 MkfDR5l1d3SxeHnjbZR6KEG|c3H5 MkDlNUBudW:uL1y= MmrnN{Bp M{mxeIJtd2OtczDzbIlsd26rbjDpcoR2[2WmIH7lZ5Jwe2m| MX6yN|g1ODR2MR?=
U87 MV;DfZRwfG:6aXPpeJkhSXO|YYm= NHfmeoMyKG2vb3yvUC=> MoDmN{Bp Mli1Zoxw[2u|IIPobYtwdmmwIHnu[JVk\WRibnXjdo9{cXN? NWjKdotQOjN6NEC0OFE>
C6 NGjHXnNHfW6ldHnvckBCe3OjeR?= MoXMNUBudW:uL1y= M2DBTVEvPS1|IHi= MVvzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJKWC1zIHPheZNm\CCkeTDzbIlsd26rbh?= MonVNlM5PDB2NEG=
U87 M{D3b2Z2dmO2aX;uJGF{e2G7 NHrUS|AyKG2vb3yvUC=> NWXCbYkzOS53LUOgbC=> MlPXd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6= NIK1bGIzOzh2MES0NS=>
TE671 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mny3OFDjiIoQvHevcYzDqA>? NYCxNmp{OjRiaB?= M{jDTZJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6 NHP1TWszOzd2NEK5Oi=>
RMS13 M4G3d2NmdGxiVnnhZoltcXS7IFHzd4F6 M4j4blQx6oDLzsznM41tyqB? M4rMWFI1KGh? MVTy[ZNkfWW|IFfYNVUuODdyLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=> NEHuNVEzOzd2NEK5Oi=>
MEFs NGH2SmxEgXSxdH;4bYNqfHliQYPzZZk> MXKyM|YwOjBizszN MoXUNVghcA>? NIDncIxqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHigbY4hWmWuQTDLU{BOTU[| NUnwcZZ5OjN5Mke1PFE>
MEFs M3jPWWZ2dmO2aX;uJGF{e2G7 NX;KZmZWOjEEoN88US=> MUOxM|IwPCCq MnGyd5VxeHKnc4Pld{BVVkcQsT3pcoR2[2WmIGLJVGsyKHCqb4PwbI9zgWyjdHnvci=> MmT4NlM4Ojd3OEG=
ΔN-Karpas 299  NYfveGxIS3m2b4TvfIlkcXS7IFHzd4F6 NHLFcZQzOMLizszN M2jLUlE3KGh? M2LwdolvcGmkaYTzJGNFOzBvaX7keYNm\CClZXzsJIRm[XSq M{n1dlI{PTR3OUO4
MM.1S  NVe2ZYMxS3m2b4TvfIlkcXS7IFHzd4F6 Mnr1PVAhyrWP NVXifWhEOSCq M3n5VIJtd2OtczDCRXkhOTFvN{C4NkBqdmS3Y3XkJJJieGmmIHPlcIwhe3enbHzpcoc> NW\meGR[OjN3MkexOVQ>
KMS-12-BM NH\ncopEgXSxdH;4bYNqfHliQYPzZZk> M1fMR|kxKML3TR?= NYPKVllQOSCq MYficI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n M1LCd|I{PTJ5MUW0
HT-22  NVPHT2F2S2WubDDWbYFjcWyrdImgRZN{[Xl? NYXvN2YyOTEEoN88US=> MYOxNuKhcA>? NE\VPGFFVVOR MYLwdo91\WO2czDh[4FqdnO2IHfseZRidWG2ZT3pcoR2[2WmIHPlcIwh\GWjdHi= M1j0blI{OzB5N{Wy
HT-22  NWPacZNjTnWwY4Tpc44hSXO|YYm= MWKyOeKh|ryP NYfOdJMxOOLCk{OwxsBucW5? MWLEUXNQ Mn7FbY5pcWKrdIOgSXJMKEGldHn2ZZRqd25iaX7keYNm\CCkeTDncJV1[W2jdHW= NWf4epdSOjN|MEe3OVI>
NIH3T3  NXHCeYt3TnWwY4Tpc44hSXO|YYm= MYqxNE82OCEQvF2= MVexM|MhcA>? NEX1fHdidWWuaX;yZZRmeyCWTldOtU1lemm4ZX6gZ49ueGyneDDmc5Ju[XSrb36= NVny[2lGOjN{NkG2O|c>
SH-EP NV22c5ZPSXCxcITvd4l{KEG|c3H5 MlzBNVDjiIoQvF5CpC=> Mo\xO|LjiImqwrC= NEP4dJZqdmirYnn0d{BKSVBiaX7obYJqfG:{LTDhcoQhVGW6YYT1cZVu[WJvaX7keYNm\CCjcH;weI9{cXN? M{\qbFIzQDlyM{Ky
HL60 MoXnRZBweHSxc3nzJGF{e2G7 Moi5OlAh|ryP MY[xNkBp NVe1Rppr\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> NWDYfpFlOjJ6M{e2PFk>
HL60/Adr NVT1ZXl4SXCxcITvd4l{KEG|c3H5 NXrRUYRIPjBizszN M{HBW|EzKGh? M{LVfoVvcGGwY3XzJJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nz NITiNGkzOjh|N{[4PS=>
K562 M4i0SGFxd3C2b4Ppd{BCe3OjeR?= MojmOlAh|ryP NWXpUoRFOTJiaB?= NWTKPZRP\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MVeyNlg{PzZ6OR?=
K562/Adr  M4HhfmFxd3C2b4Ppd{BCe3OjeR?= MWS2NEDPxE1? MUixNkBp MkT1[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MnHPNlI5Ozd4OEm=
HL60 MWjGeY5kfGmxbjDBd5NigQ>? MUS2NEDPxE1? M{HkTFEzKGh? MmHFZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? MUmyNlg{PzZ6OR?=
HL60/Adr NWDodmwxTnWwY4Tpc44hSXO|YYm= M{iyNVYxKM7:TR?= MkDVNVIhcA>? NWflW2ND[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= NX3qW5k2OjJ6M{e2PFk>
K562 NYPaOHdNTnWwY4Tpc44hSXO|YYm= NGe5dI83OCEQvF2= Mn7tNVIhcA>? M4fCToF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? MUSyNlg{PzZ6OR?=
K562/Adr  NUDxXWg4TnWwY4Tpc44hSXO|YYm= MlvROlAh|ryP MofBNVIhcA>? NUn0[IlE[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= MojzNlI5Ozd4OEm=
HL60 NX32NJRDTnWwY4Tpc44hSXO|YYm= NFPpO5k3OCEQvF2= MWKxNkBp NF;RVYZqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= NYXpTFF5OjJ6M{e2PFk>
HL60/Adr MlHHSpVv[3Srb36gRZN{[Xl? NUjreGc6PjBizszN MUCxNkBp NHnkXlJqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= NWPscm05OjJ6M{e2PFk>
K562 NWnG[ZA2TnWwY4Tpc44hSXO|YYm= MkjxOlAh|ryP NVPNdIk1OTJiaB?= NI\WV|RqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= NXS1NmtsOjJ6M{e2PFk>
K562/Adr  MXnGeY5kfGmxbjDBd5NigQ>? NInNd2Q3OCEQvF2= NYjheJViOTJiaB?= MoLxbY5kemWjc3XzJJRp\SCjY4Tpeol1gSCxZjDjZZNx[XOnczygZ4F{eGG|ZTC4JIFv\CB7 MlPHNlI5Ozd4OEm=
L929sA NIW5W3lCeG:ydH;zbZMhSXO|YYm= MV[xNEDPxE1? NF72WmYyKGh? NH;lbGpqdmirYnn0d{B1cGViYYDvdJRwfGmlIILld5BwdnOnIITvJHRPTg>? NG\oSG0zOjN4Mke2Oy=>
L929sA NV7ZO|ZrSXCxcITvd4l{KEG|c3H5 NILqZpMyOCEQvF2= M{fIOVEhcA>? NUHsS2ZPemW|Y4Xld{Bk\WyuczDlfJBz\XO|aX7nJHJKWEtzzqTJSEBnem:vIGTOSk1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYXWVHJjOjJ|NkK3Olc>
L929sA MXHBdI9xfG:|aYOgRZN{[Xl? MYixNEDPxE1? NETOUHEyKGh? MU\hZpJw\2G2ZYOgeIhmKGmwdHXyZYN1cW:wIH;mJINie3Cjc3WtPEB4cXSqIF\BSGQ> NIG3e4EzOjN4Mke2Oy=>
TPC-1 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEjsT2gyODBizszN NVLmUXRyOjRiaB?= M2HLeGROW09? M3\MeIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> NYfvTFRDOjJzM{[4NVg>
8505c NX6yOnhvS2WubDDWbYFjcWyrdImgRZN{[Xl? M2TQWlExOCEQvF2= NEHaZmIzPCCq MYjEUXNQ NYLsRlhycW6lcnXhd4V{KGOnbHz1cIFzKHO3co\peoFt M4LaT|IzOTN4OEG4
SW13 NF\oOpJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnjhNVAxKM7:TR?= NIHSO4gzPCCq M2XWVGROW09? NFX3V2FqdmO{ZXHz[ZMh[2WubIXsZZIhe3W{dnn2ZYw> MViyNlE{PjhzOB?=
Jurkat  NGfpVZREgXSxdH;4bYNqfHliQYPzZZk> NVXkSWRSPTBxIEGwNE8zODEEoN88cS=> M2rqPVEwOyCq NEPye5Rz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? M2fI[FIyPTN3MEKw
Jurkat  M2nQd2Z2dmO2aX;uJGF{e2G7 MW[yNFDDqM7:bR?= NETLV5Y{OCCvaX6= M{\JS5Jm\HWlZYRCpG5i\WeuZYLpZUBnd3euZYLpMYlv\HWlZXSgdoVi[3SrdnWgc5h6\2WwIIPw[YNq\XNiKGLPV{kh\2WwZYLheIlwdg>? M1\MW|IyPTN3MEKw
HT-22 NETw[oFEgXSxdH;4bYNqfHliQYPzZZk> Mo\WNVAh|ryP MVSxNkBp MnXndJJwfGWldIOgZYdicW6|dDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhPcLibX3vcE9NKGeudYThcYF1\cLi MXexO|c3ODh4OR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

Protocol

Kinase Assay:

[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.33
Formula

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
Synonyms N/A
Smiles CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Necrostatin-1 | Necrostatin-1 supplier | purchase Necrostatin-1 | Necrostatin-1 cost | Necrostatin-1 manufacturer | order Necrostatin-1 | Necrostatin-1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID